111 related articles for article (PubMed ID: 14987801)
21. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells.
Błasiak J; Gloc E; Młynarski W; Drzewoski J; Skórski T
Leuk Res; 2002 Dec; 26(12):1093-6. PubMed ID: 12443881
[TBL] [Abstract][Full Text] [Related]
22. The DNA-damaging potential of tamoxifen in breast cancer and normal cells.
Wozniak K; Kolacinska A; Blasinska-Morawiec M; Morawiec-Bajda A; Morawiec Z; Zadrozny M; Blasiak J
Arch Toxicol; 2007 Jul; 81(7):519-27. PubMed ID: 17593413
[TBL] [Abstract][Full Text] [Related]
23. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone.
Błasiak J; Gloc E; Warszawski M
Acta Biochim Pol; 2002; 49(1):145-55. PubMed ID: 12136935
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
26. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
Yamamoto M; Kurosu T; Kakihana K; Mizuchi D; Miura O
Biochem Biophys Res Commun; 2004 Jul; 319(4):1272-5. PubMed ID: 15194504
[TBL] [Abstract][Full Text] [Related]
27. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
28. BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin.
Slupianek A; Gurdek E; Koptyra M; Nowicki MO; Siddiqui KM; Groden J; Skorski T
Oncogene; 2005 Jun; 24(24):3914-22. PubMed ID: 15750625
[TBL] [Abstract][Full Text] [Related]
29. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
30. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
31. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
32. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.
Stoklosa T; Slupianek A; Datta M; Nieborowska-Skorska M; Nowicki MO; Koptyra M; Skorski T
Cell Cycle; 2004 Nov; 3(11):1463-72. PubMed ID: 15492510
[TBL] [Abstract][Full Text] [Related]
33. Genotoxicity of acrylamide in human lymphocytes.
Blasiak J; Gloc E; Wozniak K; Czechowska A
Chem Biol Interact; 2004 Oct; 149(2-3):137-49. PubMed ID: 15501435
[TBL] [Abstract][Full Text] [Related]
34. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
35. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
36. Differential effect of leukaemogenic tyrosine kinases on cell motility is governed by subcellular localisation.
Pierce A; Lu Y; Hamzah HG; Thompson S; Owen-Lynch PJ; Whetton AD; Spooncer E
Br J Haematol; 2006 May; 133(3):345-52. PubMed ID: 16643438
[TBL] [Abstract][Full Text] [Related]
37. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
38. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.
Slupianek A; Hoser G; Majsterek I; Bronisz A; Malecki M; Blasiak J; Fishel R; Skorski T
Mol Cell Biol; 2002 Jun; 22(12):4189-201. PubMed ID: 12024032
[TBL] [Abstract][Full Text] [Related]
39. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
40. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
